Penumbra Builds Clinical Support Showing Computer Assistance Can Better Address Clot
Vanguards of Healthcare by Bloomberg Intelligence
This is an episode of the "Vanguards of Health Care" series from Bloomberg Intelligence, featuring Matt Henriksson, a medical technology analyst, interviewing Adam Elsesser, CEO of Penumbra, a medical device company. They discuss Penumbra's computer-assisted vacuum thrombectomy (CAVT) technology, recent product launches like Lightning Flash 3.0, and the results of the STORM-PE trial, which demonstrated the effectiveness of CAVT in treating pulmonary embolism. The conversation covers the impact of the trial data on medical practice, the company's marketing strategies, and the potential of CAVT in stroke treatment with the upcoming launch of Thunderbolt. They also touch on Penumbra's embolization business and its approach to R&D and product development.
Part 1: Introduction, Core Technology
Part 2: Clinical Trials, Data Evidence
Part 3: Business Expansion, Future Innovation
Part 4: Strategy, R&D, Closing
Sign in to continue reading, translating and more.
Open full episode in Podwise
